CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO) Files An 8-K Other Events
Item 8.01. Other Events.
On October 3, 2019, Catalyst Biosciences, Inc. (the Company) issued a press release providing an update on enrollment in the Companys Phase 2b study of dalcinonacog alfa (DalcA), a next-generation subcutaneously (SQ) administered Factor IX (FIX) therapy being developed for the treatment of hemophilia B. DalcA. The commencement of enrollment under the DalcA clinical trial was originally announced on April 2, 2019. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| 99.1 | | Press Release dated October 3, 2019. |
CATALYST BIOSCIENCES, INC. Exhibit
EX-99.1 2 d788434dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Catalyst Biosciences Provides DalcA Phase 2b Trial Update Two subjects have successfully completed dosing,…
To view the full exhibit click here
About CATALYST BIOSCIENCES, INC. (NASDAQ:CBIO)
Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
